--- title: "Nanobiotix Prices Global Equity Offering with Long-Dated Pre-Funded Warrants" type: "News" locale: "en" url: "https://longbridge.com/en/news/287685763.md" description: "Nanobiotix has announced a global equity offering of 225,373 American Depositary Shares in the U.S. and 1,959,289 ordinary shares in Europe, along with 345,099 pre-funded warrants. The transaction aims to strengthen the company's capital base and is expected to close around May 26, 2026. Analysts rate NBTX stock as a Buy with a $36.00 price target, though concerns about financial fundamentals persist." datetime: "2026-05-26T22:21:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287685763.md) - [en](https://longbridge.com/en/news/287685763.md) - [zh-HK](https://longbridge.com/zh-HK/news/287685763.md) generator: "portal-rs" --- # Nanobiotix Prices Global Equity Offering with Long-Dated Pre-Funded Warrants ### Memorial Day Sale – Claim 70% Off TipRanks - Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. - Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Nanobiotix ( (NBTX) ) has shared an announcement. On May 21, 2026, Nanobiotix entered an underwriting agreement with a syndicate led by Jefferies and TD Securities for a global equity offering of 225,373 American Depositary Shares in the U.S. and 1,959,289 ordinary shares in Europe, alongside 345,099 pre-funded warrants issued to certain investors in lieu of ordinary shares. The transaction, including the fully exercised U.S. over-allotment option of 33,805 ADSs and detailed terms limiting and governing exercise of the long-dated pre-funded warrants through May 26, 2036, is expected to close around May 26, 2026 and is set to strengthen the company’s capital base while modestly diluting existing shareholders and broadening its transatlantic investor base. The pre-funded warrants will be recorded in book-entry form only, carry a nominal remaining exercise price of €0.03 per share, and are exercisable at any time over ten years subject to ownership caps that prevent holders from exceeding specified beneficial ownership thresholds without regulatory clearance. Nanobiotix also reserves the right to temporarily suspend warrant exercises in defined corporate actions and will adjust warrant terms under French commercial law in the event of capital operations, underscoring a structured approach to balancing investor flexibility with regulatory and corporate governance constraints. The most recent analyst rating on (NBTX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page. **Spark’s Take on NBTX Stock** According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral. The score is primarily constrained by weak financial fundamentals (ongoing losses, cash burn, and balance-sheet pressure including negative equity and higher leverage). Offsetting this are strong technical momentum (though extended) and a constructive earnings-call outlook emphasizing improved runway and multiple clinical catalysts, while valuation support is limited given negative earnings and no dividend. To see Spark’s full report on NBTX stock, click here. **More about Nanobiotix** Nanobiotix S.A. is a France-based biotechnology company whose securities trade in the form of ordinary shares in Europe and American Depositary Shares in the U.S. The company finances its activities through global equity and equity-linked offerings targeting qualified investors in Europe and institutional investors in the United States. **Average Trading Volume:** 80,808 **Technical Sentiment Signal:** Buy **Current Market Cap:** $2.05B ### Related Stocks - [NBTX.US](https://longbridge.com/en/quote/NBTX.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [TD.US](https://longbridge.com/en/quote/TD.US.md) ## Related News & Research - [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md) - [Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer](https://longbridge.com/en/news/286776980.md) - [Nanobiotix Resumes Trading Of Ordinary Shares On Euronext Paris](https://longbridge.com/en/news/287242199.md) - [Nanobiotix (NASDAQ:NBTX) Hits New 1-Year High - Here's What Happened](https://longbridge.com/en/news/285538784.md) - [FY2027 EPS Estimates for Nanobiotix Decreased by Analyst](https://longbridge.com/en/news/281917063.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**